ANN ARBOR, Mich., May 9, 2017 /PRNewswire/ -- HistoSonics, Inc., a venture-backed medical device company, announced that it has been selected to present at the jointly-hosted Michigan Growth Capital Symposium (MGCS) and Coulter Investment Forum to an audience of more than 100 top venture capital firms.
HistoSonics CEO & President Mike Blue will present the company's plans to offer a new platform in cancer care: a non-invasive, highly precise, and cost-effective method of tumor destruction called Robotically Assisted Sonic Therapy (RAST)™. This new modality in development – which is non-thermal and does not use ionizing radiation – has the potential to treat a broad range of cancers in an outpatient setting without the incisions, punctures, pain, and long recovery times associated with existing methods of cancer treatment.
To continue its development efforts, HistoSonics recently closed an $8.3 million Series B round with existing investors, joined by the University of Michigan's Wolverine Venture Fund. The company anticipates a Series C financing during the second half of 2017 to accelerate significant product development and regulatory milestones.
"We are proud to be part of this exciting event," said Mr. Blue. "MGCS always provides a terrific opportunity to connect (or reconnect) with investors. We're particularly pleased to be presenting this year due to the involvement of the Coulter Foundation, which has generously supported our scientific founders' efforts to translate the groundbreaking technology of histotripsy from the lab to patient care."
First held in 1981, MGCS is the premier event for venture capitalists, technology transfer professionals, founders, CEOs and the best of the Midwest early stage and emerging, high-growth companies that are seeking institutional investment. The two-day conference will feature keynote addresses from Clay Thorp, general partner of Hatteras Venture Partners, and Markus Lampinen, CEO of Crowd Valley, along with engaging panel discussions and unmatched networking opportunities for attendees.
More than 500 entrepreneurs, researchers, investment professionals and business executives are expected to attend the Symposium, which will be held May 16-17 at the Marriott Resort in Ypsilanti, Mich. The evening reception on the opening day of the conference at the University of Michigan's football stadium will provide attendees the chance to network on and off the field.
"The Symposium plays a vital role in the Midwest's entrepreneurial ecosystem, creating a platform for high-growth companies to make their case to investors and access new sources of funding," said David Brophy, Michigan Growth Capital Symposium founder and director of the University of Michigan's Center for Venture Capital & Private Equity. "I am continually impressed by the caliber of companies that join us to present year after year, and we are glad to have HistoSonics join the ranks for this year's special joint event with the Coulter Investment Forum."
To learn more about MGCS, see the full list of presenting companies, or register for the conference, visit www.michigan-gcs.com and follow conversations about the Symposium by tracking #MichiganGCS on Twitter. For more information about HistoSonics, please visit www.histosonics.com.
HistoSonics, Inc. was created to advance the development of histotripsy, a revolutionary science discovered and developed by leading scientists at the University of Michigan to provide improved therapies for patients. Our exclusive license to intellectual property, significant financial support, and strategic partnerships have helped HistoSonics develop Robotically Assisted Sonic Therapy (RAST)TM, a non-invasive, non-thermal approach to cancer care that is based on the science of histotripsy, using pulsed sound energy for the precise destruction of targeted tissues. HistoSonics' team of experienced specialists and industry leaders is based in Ann Arbor, Michigan. To learn more, please visit www.histosonics.com.
About the Michigan Growth Capital Symposium
The Michigan Growth Capital Symposium (MGCS) is the original university-based venture investment fair, which was first held in 1981. This decades-old nationally attended event is the largest Midwest fair of its kind that brings together venture capital investors, business angels, start-up companies, university tech transfer officers and research faculty. MGCS provides an opportunity for participants from the venture capital community to connect with Midwest start-ups seeking funding and to learn about emerging innovations that span tech and the life sciences. MGCS is presented by the Center for Venture Capital & Private Equity Finance and the Zell Lurie Institute at the University of Michigan Ross School of Business, with support from the Michigan Venture Capital Association.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/histosonics-to-present-at-the-36th-annual-michigan-growth-capital-symposium-and-coulter-investment-forum-may-16-17-300454079.html
SOURCE HistoSonics, Inc.